Please assess the completion status of the following clinical trial:

Trial Title: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 15-80 years (US only), and 18-80 (rest of world (ROW)), male or female.~* Adjuvant or neoadjuvant chemotherapy (including doxorubicin) allowed if no tumor recurrence for at least 12 months since the last measurement, beginning or end of last chemotherapy.~* Histologically or cytologically confirmed, locally advanced, unresectable, and/or metastatic soft tissue sarcoma of intermediate or high grade.~* Capable of providing informed consent and complying with trial procedures.~* ECOG performance status 0-2.~* Life expectancy \> 12 weeks.~* Measurable tumor lesions according to RECIST 1.1 criteria.~* Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. (Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.)~* Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.~* Geographic accessibility to the site that ensures the subject will be able to keep all study-related appointments.~Exclusion Criteria:~* Prior chemotherapy unless for adjuvant or neoadjuvant therapy with no tumor recurrence for at least 12 months.~* Prior exposure to \> 3 cycles or 225 mg/m2 of doxorubicin or Doxil®.~* Palliative surgery and/or radiation treatment less than 4 weeks prior to Randomization.~* Exposure to any investigational agent within 30 days of Randomization.~* Current Stage 1 or 2 soft tissue sarcomas.~* Current evidence/diagnosis of alveolar soft part sarcoma, chondrosarcoma, rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor (GIST), dermatofibrosarcoma, Ewing's sarcoma, Kaposi's sarcoma, mixed mesodermal tumor, clear cell sarcomas and unresectable low grade liposarcomas.~* Central nervous system metastasis~* History of other malignancies except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix unless documented free of cancer for \> 5 years.~* Laboratory values: Screening serum creatinine \> 1.5x upper limit of normal (ULN), alanine aminotransferase (ALT) \> 3 × ULN or \>5 × ULN if liver metastases are present, total bilirubin \> 3 × ULN, absolute neutrophil count \< 1,500/mm3, platelet concentration \< 100,000/mm3, hematocrit level \< 25% for females or \< 27% for males, or coagulation tests (prothrombin time \[PT\], partial thromboplastin time \[PTT\], International Normalized Ratio \[INR\]) \> 1.5 × ULN, albumin \< 2.0 g/dL.~* Clinically evident congestive heart failure \> class II of the New York Heart Association (NYHA) guidelines.~* Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.~* Baseline QTc \> 470 msec and/or previous history of QT prolongation while taking other medications. Concomitant use of medications associated with a high incidence of QT prolongation is not allowed.~* History or signs of active coronary artery disease with or without angina pectoris.~* Serious myocardial dysfunction defined as scintigraphically (e.g. MUGA, myocardial scintigram) or ultrasound determined absolute left ventricular ejection fraction (LVEF) \< 45% of predicted.~* History of HIV infection.~* Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals.~* Major surgery within 3 weeks prior to Randomization.~* Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.~* Any condition that is unstable and could jeopardize the subject's participation in the study.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Doxorubicin (Type: ACTIVE_COMPARATOR): None
- INNO-206 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).